Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 383

1.

Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen.

Fraser IS, Weisberg E, Brache V, Alvarez F, Massai R, Mishell DR Jr, Apter D, Gale J, Tsong YY, Sivin I.

Contraception. 2005 Jul;72(1):40-5.

PMID:
15964291
[PubMed - indexed for MEDLINE]
2.

Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen.

Weisberg E, Brache V, Alvarez F, Massai R, Mishell DR Jr, Apter D, Gale J, Sivin I, Tsong YY, Fraser IS.

Contraception. 2005 Jul;72(1):46-52.

PMID:
15964292
[PubMed - indexed for MEDLINE]
3.

A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.

Weisberg E, Fraser IS, Mishell DR Jr, Lacarra M, Darney P, Jackanicz TM.

Contraception. 1999 May;59(5):305-10.

PMID:
10494484
[PubMed - indexed for MEDLINE]
4.

Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.

Weisberg E, Fraser IS, Lacarra M, Mishell DR Jr, Alvarez F, Brache V, Nash HA.

Contraception. 1999 May;59(5):311-8.

PMID:
10494485
[PubMed - indexed for MEDLINE]
5.

Feasibility study of Nestorone-ethinylestradiol vaginal contraceptive ring for emergency contraception.

Croxatto HB, Brache V, Massai R, Alvarez F, Forcelledo ML, Pavez M, Cochon L, Salvatierra AM, Faundes A.

Contraception. 2006 Jan;73(1):46-52. Epub 2005 Nov 14.

PMID:
16371294
[PubMed - indexed for MEDLINE]
6.

Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.

Alvarez-Sanchez F, Brache V, Jackanicz T, Faundes A.

Contraception. 1992 Oct;46(4):387-98.

PMID:
1486777
[PubMed - indexed for MEDLINE]
7.

Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial.

Sivin I, Mishell DR Jr, Alvarez F, Brache V, Elomaa K, Lähteenmäki P, Massai R, Miranda P, Croxatto H, Dean C, Small M, Nash H, Jackanicz TM.

Contraception. 2005 Feb;71(2):122-9.

PMID:
15707562
[PubMed - indexed for MEDLINE]
8.

Suppression of ovarian function with the transdermally given synthetic progestin ST 1435.

Laurikka-Routti M, Haukkamaa M, Lähteenmäki P.

Fertil Steril. 1992 Oct;58(4):680-4.

PMID:
1426309
[PubMed - indexed for MEDLINE]
9.

Ovarian function during use of vaginal rings delivering three different doses of Nestorone.

Brache V, Mishell DR, Lahteenmaki P, Alvarez F, Elomaa K, Jackanicz T, Faundes A.

Contraception. 2001 May;63(5):257-61.

PMID:
11448466
[PubMed - indexed for MEDLINE]
10.

Ovarian function during use of Nestorone(R) subdermal implants.

Brache V, Massai R, Mishell DR, Moo-Young AJ, Alvarez F, Salvatierra AM, Cochon L, Croxatto H, Robbins A, Faundes A.

Contraception. 2000 Mar;61(3):199-204.

PMID:
10827334
[PubMed - indexed for MEDLINE]
11.

A detailed analysis of menstrual blood loss in women using Norplant and Nestorone progestogen-only contraceptive implants or vaginal rings.

Fraser IS, Weisberg E, Minehan E, Johansson ED.

Contraception. 2000 Apr;61(4):241-51.

PMID:
10899479
[PubMed - indexed for MEDLINE]
12.

Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.

Sitruk-Ware RL, Menard J, Rad M, Burggraaf J, de Kam ML, Tokay BA, Sivin I, Kluft C.

Contraception. 2007 Jun;75(6):430-7. Epub 2007 Mar 26.

PMID:
17519148
[PubMed - indexed for MEDLINE]
13.

A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry.

Laurikka-Routti M, Haukkamaa M, Heikinheimo O.

Contraception. 1990 Jul;42(1):111-20.

PMID:
2387151
[PubMed - indexed for MEDLINE]
14.

Ovarian activity during regular oral contraceptive use.

Crosignani PG, Testa G, Vegetti W, Parazzini F.

Contraception. 1996 Nov;54(5):271-3.

PMID:
8934059
[PubMed - indexed for MEDLINE]
15.

Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: ovarian function, bleeding control and lipoprotein patterns.

Victor A, Lithell H, Selinus I, Vessby B.

Ups J Med Sci. 1984;89(2):179-88.

PMID:
6380076
[PubMed - indexed for MEDLINE]
16.

Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition.

Mulders TM, Dieben TO.

Fertil Steril. 2001 May;75(5):865-70.

PMID:
11334895
[PubMed - indexed for MEDLINE]
17.

Correlation of endocrine profiles with bleeding patterns during use of Nestorone contraceptive implants.

Faúndes A, Alvarez F, Brache V, Cochón L, Tejada AS, Moo-Young A.

Hum Reprod. 1999 Dec;14(12):3013-7.

PMID:
10601089
[PubMed - indexed for MEDLINE]
Free Article
18.

Complete and robust ovulation inhibition with NuvaRing.

Killick S.

Eur J Contracept Reprod Health Care. 2002 Dec;7 Suppl 2:13-8; discussion 37-9. Review.

PMID:
12659397
[PubMed - indexed for MEDLINE]
19.

A contraceptive subdermal implant releasing the progestin ST-1435: ovarian function, bleeding patterns, and side effects.

Laurikka-Routti M, Haukkamaa M.

Fertil Steril. 1992 Dec;58(6):1142-7.

PMID:
1459263
[PubMed - indexed for MEDLINE]
20.

Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen.

Archer DF, Kovalevsky G, Ballagh SA, Grubb GS.

Contraception. 2009 Sep;80(3):245-53. doi: 10.1016/j.contraception.2009.03.006. Epub 2009 May 2.

PMID:
19698816
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk